Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M503086200 on September 12, 2005

J. Biol. Chem., Vol. 280, Issue 46, 38569-38575, November 18, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/46/38569    most recent
M503086200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barran, P. E.
Right arrow Articles by Millar, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barran, P. E.
Right arrow Articles by Millar, R. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Evolution of Constrained Gonadotropin-releasing Hormone Ligand Conformation and Receptor Selectivity*

Perdita E. Barran{ddagger}, Roger W. Roeske§, Adam J. Pawson¶, Robin Sellar¶, Michael T. Bowers||, Kevin Morgan¶, Zhi-Liang Lu¶, Motoyuki Tsuda**, Takehiro Kusakabe**, and Robert P. Millar¶{ddagger}{ddagger}1

From the {ddagger}School of Chemistry, The University of Edinburgh, Edinburgh EH9 3JJ, United Kingdom, §School of Medicine, Indiana University, Indiana 46202-5122, MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom, ||Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9510, **Department of Life Science, Himeji Institute of Technology, Hyogo 678-1297, Japan, and {ddagger}{ddagger}Department of Medical Biochemistry, University of Cape Town, Observatory 7925, Cape Town, South Africa

Received for publication, March 21, 2005 , and in revised form, August 11, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Gonadotropin-releasing hormone (GnRH) is the central regulator of reproduction in vertebrates. GnRHs have recently been identified in protochordates and retain the conserved N- and C-terminal domains involved in receptor binding and activation. GnRHs of the jawed vertebrates have a central achiral amino acid (glycine) that favors a type II' {beta}-turn such that the N- and C-terminal domains are closely apposed in binding the GnRH receptor. However, protochordate GnRHs have a chiral amino acid in this position, suggesting that they bind their receptors in a more extended form. We demonstrate here that a protochordate GnRH receptor does not distinguish GnRHs with achiral or chiral amino acids, whereas GnRH receptors of jawed vertebrates are highly selective for GnRHs with the central achiral glycine. The poor activity of the protochordate GnRH was increased >10-fold at vertebrate receptors by replacement of the chiral amino acid with glycine or a D-amino acid, which favor the type II' {beta}-turn. Structural analysis of the GnRHs using ion mobility-mass spectrometry and molecular modeling showed a greater propensity for a type II' {beta}-turn in GnRHs with glycine or a D-amino acid, which correlates with binding affinity at vertebrate receptors. These findings indicate that the substitution of glycine for a chiral amino acid in GnRH during evolution allows a more constrained conformation for receptor binding and that this subtle single amino acid substitution in a site remote from the ligand functional domains has marked effects on its structure and activity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In vertebrates, gonadotropin-releasing hormone (GnRH)2 is synthesized in hypothalamic neurones and conducted a few millimeters in the hypophysial portal system to the anterior pituitary, where it binds to high affinity receptors in gonadotrophs to stimulate the release of gonadotropins (1). The gonadotropins in turn stimulate hormone and gamete production by the testes and ovaries. GnRHs have also been isolated from protochordate species (2, 3) and are thought to be secreted from neurones to directly regulate the gonads (2-4) in these representatives of vertebrate progenitors. GnRHs and GnRH receptors have also been found to directly affect vertebrate gonadal function (5), possibly reflecting the earliest role of GnRH as exemplified in protochordates (6, 7). It appears, therefore, that GnRHs have an ancient evolutionary role as regulators of reproduction, first through direct neural delivery to the gonads and later as hypothalamic neuroendocrine regulators of the gonads indirectly through gonadal stimulation by gonadotropins.

To date 13 structural variants of the GnRH decapeptide have been identified in vertebrates (8), 9 from protochordates, which are vertebrate progenitors (8, 9), and a 12-amino acid homolog from an octopus species (10) (Fig. 1). All of the GnRHs are characterized by the conservation of the N-terminal residues (pGlu-His-Trp-Ser) and the C-terminal residues (Pro-Gly-NH2) with the exception of two conservative substitutions (Fig. 1). In cartilaginous and bony fish, amphibians, reptiles, birds, and mammals, all of the GnRHs are further characterized by the presence of a glycine residue in position six (Fig. 1). Being archiral, the glycine residue allows the peptide to assume a type II' {beta}-turn conformation, which is essential for high binding affinity and biological activity in mammals (1, 8, 11, 12). Substitution of glycine with any other L-amino acid decreases biological activity as the type II' {beta}-turn conformation is less favored (1, 8, 11, 12). In contrast, substitution of glycine with D-amino acids in position six constrains the peptide to the type II' {beta}-turn conformation and increases binding affinity and biological activity in mammals, birds, amphibians, and jawed fish species (1, 6–8, 11, 12).

The GnRHs in the ancient jawless lamprey and protochordate species (with the exception of Ciona VI) are all characterized by the presence of chiral amino acids in position six (Fig. 1). This feature is likely to limit the formation of a type II' {beta}-turn conformation, and these GnRHs would be expected to have correspondingly low binding affinities and biological activities at GnRH receptors of higher vertebrates (1, 6, 7, 12).

We, therefore, hypothesized that early in evolution GnRH interacted with the GnRH receptor in a more relaxed (linear) conformation. Coincident with the evolution of the jawed fish, structural changes in GnRH and its receptor required the peptide to interact in the folded type II' {beta}-turn conformation. To investigate this notion, we have synthesized and studied the structure and biological activity of three GnRHs from a tunicate protochordate (Ciona intestinalis) at catfish, chicken, human, and protochordate GnRH receptors. We demonstrate that these protochordate GnRHs have low biological activity at jawed vertebrate GnRH receptors but that high biological activity is generated when the natural chiral amino acid in position six is replaced by the achiral glycine, which is characteristic of jawed vertebrate GnRHs. We also studied the structure of these peptides employing a combination of ion mobility-mass spectrometry (IM-MS) and molecular modeling and demonstrated a correlation of the biological activity at vertebrate receptors with the ability of the peptides to assume the folded more compact conformation. These findings reveal a co-evolution of GnRH and its cognate receptor in which the receptors of early evolved organisms bind an extended structure of GnRH, whereas the receptors of higher organisms require a folded type II' {beta}-turn conformation of GnRH in which the N and C termini are in close apposition when bound to the receptor.



View larger version (46K):
[in this window]
[in a new window]
  		FIGURE 1.
Primary amino acid sequences of naturally occurring decapeptide GnRH structural variants spanning ~600 million years of evolution. The boxed regions show the conserved N- and C-terminal residues that are involved in receptor binding and activation. The GnRHs are named according to the species in which they were first discovered, and they may be represented in more than one species. For example, mammalian GnRH is widely conserved in amphibians and primitive bony fish, and chicken GnRH II is present in most vertebrate species, including man. An octopus GnRH and an additional Ciona GnRH comprising 12 and 16 amino acids, respectively, but retaining the conserved N- and C-terminal domains are not shown.

 

   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Peptides—Ciona I, II, and III GnRH, Gly6-Ciona I GnRH, and D-Ala6-Ciona I GnRH were synthesized by conventional solid phase methodology and purified by high performance liquid chromatography to >98% purity. Mammalian GnRH was from Peninsula Laboratories (Bachem Ltd., Merseyside, UK).

Cell Culture and Transient Transfection—Plasmid DNA for transient transfection was prepared using Maxi-Prep columns (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. COS-7 and human embryonic kidney 293 cells were cultured as previously described for COS-1 cells (12, 13) and transiently transfected with the human (14), chicken (15), and catfish (16) GnRH receptors as well as the recently cloned Ciona receptors (17)3 using electroporation. These are Ciona A and Ciona B GnRH receptors previously referred to as Ci-GnRHR1 and Ci-GnRHR2.

Receptor Binding Assays—Whole cell receptor binding assays used the 125I-[His5,D-Tyr6]GnRH analog for the vertebrate receptors and 125I-GnRH II for the Ciona receptor (13). Transiently transfected COS-7 cells in 12-well culture plates were washed once with ice-cold HEPES, Dulbecco's modified Eagle's medium, 10% fetal calf serum and incubated for 5 h on ice in the same medium with 106 cpm/well radiolabeled GnRH analog and varying concentrations of unlabeled GnRH peptides (13). Cell monolayers were then rapidly washed twice in ice-cold phosphate-buffered saline and solubilized in 0.1 M NaOH, and the lysate radioactivity was counted. Nonspecific binding (consistently less than 10% of total binding) was determined using vector-transfected (pcDNA1/amp) COS-7 cells and subtracted from total binding to give specific binding. Assays were conducted in triplicate and repeated in three separate experiments.

Total Inositol Phosphate Assays—GnRH stimulation of total inositol phosphate production was assayed as previously described (18, 19). Briefly, transiently transfected COS-7 cells were incubated with inositol-free Dulbecco's modified Eagle's medium containing 1% dialyzed heat-inactivated fetal calf serum and 0.5 µCi/well myo-[3H]inositol (Amersham Biosciences) for 48 h. Medium was removed, and the cells were washed with 1 ml of buffer (140 mM NaC1, 20 mM HEPES, 4 mM KC1, 8 mM glucose 1 mM MgC12, 1 mM CaC12, and 1 mg/ml bovine serum albumin) containing 10 mM LiC1 and incubated for 1 h at 37 °C in 0.5 ml of buffer containing 10 mM LiCl and GnRH agonist at the indicated concentrations. Reactions were terminated by the removal of agonist and the addition of 1 ml of ice-cold 10 mM formic acid, which was incubated for 30 min at 4 °C. Total [3H]inositol phosphates were separated from the formic acid cell extracts on AG-X8 anion exchange resin (Bio-Rad) and eluted with a 1 M ammonium format, 0.1 M formic acid solution. The associated radioactivity was determined by liquid scintillation counting. Assays were conducted in triplicate and repeated in three separate experiments.

Ion Mobility-Mass Spectrometry—The gas-phase collision cross-sections of mammalian GnRH, Ciona 1 GnRH, and its two substituted derivates were determined using an ion mobility mass spectrometer, as previously described (20). Briefly, ions created by electrospray ionization are injected into a temperature-regulated drift cell pressurized with helium to 5 torr. The ions drift under the influence of a weak electrostatic field and are retarded by collisions with the buffer gas. On exiting the cell, ions are selected by a quadrupole mass filter, and their arrival time distributions are recorded. Arrival times are collected at several drift voltages, and the mobility (K) of the ion is obtained from the gradient of a plot of arrival time versus the pressure of helium divided by the drift voltage. This mobility is used to determine the experimental collision cross-section of the ion ({sigma}) according to the equation K = [(3e)/(16N)][(2{pi})/(µ{kappa}BT)]1/2[1/{sigma}] as described (21).

Molecular Structures of GnRH Peptides—Analysis of the structures of mammalian GnRH, Ciona I GnRH, and two substituted Ciona I variants was conducted using molecular mechanics. All calculations were performed using the ff99 AMBER force field (22), employing the Amber7 suite of programs to refine the energy of the peptide models. Residues for the N-terminal pyrolyzed glutamic acid and the amidated glycine present at the C terminus generated using the RESP procedure (23) and the ANTECHAMBER facility within the Amber 7 suite of programs (amber.scripps.edu). IM-MS data were obtained for these peptides both as singly ([M+H]+) and doubly ([M+2H]2+) protonated ions. From gas-phase basicities (24) it is most probable that Arg8 in mammalian GnRH will be protonated in [M+H]+and that the [M+2H]2+ ion will contain protonated His2. In the protochordate Ciona I peptides, Arg8 is substituted by Ser8, and it is extremely likely that their [M+H]+ ions contain protonated histidine. The protonation state of His2 is variable in physiological conditions, and therefore calculations were performed with both protonated and unprotonated histidine for the Ciona I peptides and for the singly and doubly protonated form of mammalian GnRH. At most physiological pH values, Arg8 of mammalian GnRH will be protonated; hence, calculations on the neutral species have not been performed for this peptide. The Ciona I [M+2H]2+ ions probably arise due to protonation of the amide Gly10; however, since we cannot determine the biological significance of this chemical form and due to some ambiguity in assigning this site of charge, the doubly protonated peptides were not investigated further in this study. For each of these 8 chemically distinct peptides, 300 candidate gas-phase minimized structures were generated using a simulated annealing approach. An initial structure was subjected to dynamics at 800 K for 30 ns and then cooled in a stepwise fashion to 0 K before an energy minimization. This minimized structure was then used as the seed for the next cycle. The two lowest energy structures for each species were then subjected to 1 ns of molecular mechanics at 300 K for the [M+H]+ ions. This was performed in vacuo and employing the Born Solvent distance-dependent dielectric model to simulate their dynamic structure in an aqueous environment (25). For the neutral Ciona I peptides, these extended dynamics calculations were only performed with the use of the solvent model. This procedure generates 1000 co-ordinate files for each 1 ns, i.e. co-ordinates are saved every ps, with the potential energy surface sampled every fs. No weighting was given to any of the amino acids, and translational energies are removed every ps. Each molecular mechanics data set was analyzed, and conformational variables such as the N-C termini distance and overall peptide flexibility were compared with those found for mammalian GnRH examined under identical conditions. Collision cross-sections for each low energy structure obtained via the simulated annealing procedure were calculated using the projection approximation (26). This was also employed to elucidate conformational changes occurring to these peptides during molecular dynamics.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Receptor Binding—All three Ciona GnRHs had low affinity for the human receptor (IC50 > 1 µM) in comparison to mammalian GnRH (7.5 nM) (Fig. 2A, TABLE ONE). Similar results were found in binding of these peptides to the chicken and catfish (data not shown) GnRH receptors. In contrast Ciona I and Ciona II had low affinities (918 and 988 nM) at the Ciona A receptor, which were similar to that of mammalian GnRH (1390 nM) (Fig. 2B). Ciona II had a considerably lower affinity (5600 nM) and may be the cognate ligand for a second Ciona GnRH receptor (17), which expressed poorly and, therefore, did not allow binding studies (data not shown). Because Ciona I was the most active of the Ciona peptides at the human receptor, this was selected for studies to determine whether substitution of the chiral amino acid in position six would increase activity at the human receptor. Replacement of Ala6 with the achiral Gly6 or with the type II' {beta}-turn-constraining D-Ala6 resulted in a marked increase (36–46-fold) in binding affinity (Fig. 2C, TABLE ONE). Similar results were obtained for the chicken (Fig. 2D) and catfish (data not shown) GnRH receptors.


View this table:
[in this window]
[in a new window]
  		TABLE ONE
Receptor binding and inositol phosphate production by mammalian and Ciona GnRHs and analogues at the human GnRH receptor expressed in COS-7 cells

 



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 2.
Binding of mammalian, Ciona, and position-six substituted Ciona I GnRHs to human, Ciona A, and chicken GnRH receptors. COS-7 cells were transfected with human, Ciona A, and chicken GnRH receptors, incubated with radiolabeled GnRH analogs and increasing doses of unlabeled GnRHs and analogs in triplicate, and washed in phosphate-buffered saline at 4 °C, and the bound radioactivity was determined as described under "Experimental Procedures." Points are the mean ± S.E. (within the symbol size). Similar results to C and D were obtained with the catfish receptor (not shown). A and B, filled squares, mammalian GnRH; filled triangles, Ciona I GnRH; open triangles, Ciona II GnRH; open circles, Ciona III GnRH. C and D, filled squares, mammalian GnRH; filled triangles, Ciona I GnRH; filled circles, Gly6-Ciona I GnRH; open squares, D-Ala6-Ciona I GnRH.

 
Inositol Phosphate Production—The three Ciona peptides were at least 3 orders of magnitude less potent than mammalian GnRH at stimulating inositol phosphate production (Fig. 3, TABLE ONE). Their relative activities paralleled that of their binding affinities. Substitution of Ala6 with Gly6 or D-Ala6 increased the potency more than 100-fold.

Ion Mobility-Mass Spectrometry and Molecular Modeling of GnRH Peptides—Experimental cross-sections measured for the [M+H]+ ions of mammalian GnRH, Ciona I, and Ciona II GnRH analogs are given in TABLE TWO. Agreement between the measured and calculated values is very good. The gas-phase cross-section of mammalian GnRH is smaller than that obtained for the Ciona I GnRH, and substitution of L-Ala6 with D-Ala6 or Gly6 reduces the cross-section to approach that of mammalian GnRH. Fig. 4 shows representative low energy structures obtained from the in vacuo simulations of the peptide ions. The general conformation of all of the peptides is comparable, as might be expected based on their sequence homologies. All form compact structures with a hairpin shape to the polypeptide backbone, which is sustained through non-covalent interactions across this structure. The radius is larger for the Ciona I form than that found for the Gly6- or D-Ala6-substituted Ciona I (Fig. 4), in agreement with the IM-MS cross-section data (TABLE TWO). Cross-sections obtained from the geometry calculations with unprotonated histidine are also included.


View this table:
[in this window]
[in a new window]
  		TABLE TWO
Collision cross-sections for the [M+H]+ GnRH peptide ions measured experimentally and those obtained from the low energy candidate conformations Values in parentheses are the range of cross-sections observed for the lowest 10% of structures. Calculated collision cross-sections for the neutral peptides are listed in the third column.

 



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 3.
Stimulation of inositol phosphate production by mammalian and Ciona GnRHs, and position-six substituted analogues at the human GnRH receptor. COS-7 cells were transfected with the human GnRH receptor, incubated with myo-[3H]inositol and then GnRH analogs at increasing concentrations in the presence of LiCl, and total [3H]inositol phosphates were determined as described under "Experimental Procedures." Points are the mean ± S.E. of triplicates. Filled squares, mammalian GnRH; filled triangles, Ciona I GnRH; open triangles, Ciona II GnRH; open circles, Ciona III GnRH; filled circles, Gly6 Ciona I GnRH; open squares, D-Ala6 Ciona I GnRH.

 
By performing molecular dynamics on these low energy structures, the conformational space available to them is sampled, thus probing the stability of interactions formed. This was conducted both in vacuo and also with the application of a solvent model. Conformations obtained with the Born Solvent model are presumed to be more representative of biologically active conformations, at least before receptor binding. Several criteria were examined in the room temperature dynamics, and our findings are summarized below and in TABLE THREE.


View this table:
[in this window]
[in a new window]
  		TABLE THREE
Table showing the average results of co-ordinate analysis from extended dynamics calculations Listed are average N-C distances (C{alpha}-C{alpha}), the distance between Trp3 and Leu7, and the collision cross-sections of the confirmation from co-ordinates averaged over 1 ns of dynamics performed at 300 K. The figure given is averaged from those obtained from two molecular dynamic runs. The standard deviation from this value is given in parentheses.

 
N- to C-terminal Distance—The proposal that GnRH binds the GnRH mammalian receptor in a type II' {beta}-turn conformation suggests non-covalent interactions which position the N- and C-terminal residues closely apposed in space. The low energy gas-phase structures determined here fulfill this criterion (Fig. 4). Over the 1-ns dynamics runs, the persistence of this interaction was explored by plotting the distance between the {alpha} carbons of the N-terminal pyrolyzed glutamic acid and the C-terminal glycine amide. The in vacuo simulations for mammalian GnRH and Ciona I GnRH and analogs reveal a continual N-C-terminal proximity, which bears out the analysis made above on the low energy conformation (TABLE THREE). It is apparent that the distance between the {alpha} carbons decreases as residue 6 is replaced by D-Ala or achiral glycine. With application of the Born Solvent distance dielectric function, Ciona I GnRH exhibits a somewhat larger average N-C-terminal variation than D-Ala6-Ciona and significantly larger than for Gly6-Ciona I (TABLE THREE). Mammalian GnRH displays a more rigid conformation, with less deviation from the average N-C distance than the Ciona I peptides. However, all of the forms of GnRH experience an opening of the peptide backbone within the higher dielectric environment, resulting in a larger average N-C-terminal distance as seen in representative structures obtained from the dynamics runs under Born Solvent conditions (Fig. 5).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 4.
Ribbon representations of peptide structures. The peptide backbone for the [M+H]+ ions of Ciona I (a), Gly6 Ciona I (b), D-Ala6 Ciona I (c), and mammalian GnRH (d) are shown. Each is a snapshot from in vacuo dynamics calculations. The amidated N-terminal glycine is shown in each, as is residue six and the proton-carrying residue. As described under "Results" and in TABLE THREE, the cross-peptide radius for Ciona I peptide is larger than for the other peptides (b, c, and d), which possesses a tighter turn around residues 5 and 6. In all of these peptides the proton carrying group (histidine for the Ciona peptides and arginine for mammalian GnRH) "caps" the polypeptide ring, thereby providing points for non-covalent interactions that stabilize these compact geometries of gas-phase ions.

 
Trp3-Leu7 Distances—Although it is clear that the GnRH peptides exhibit considerable conformational flexibility, their dominant structural feature is a type II' {beta}-turn between residues 5 and 8. The increase in receptor binding affinity when the achiral Gly or D-Ala is substituted for the chiral L-Ala in Ciona I GnRH is attributed to a release in steric hindrance allowing for a tighter hinge to the peptide backbone. We have examined the distance between Trp3 and Leu7 as a possible indicator of hinge mobility. For Ciona I and the substituted analogs, the average distance between these residues is remarkably similar (TABLE THREE).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 5.
Ribbon representations of peptide structures. The peptide backbone of Ciona I (a), Gly6 Ciona I (b), and mammalian GnRH (c) are shown. The Ciona I peptides contain protonated His2, and mammalian GnRH has Arg8 and His2, both, protonated. Each is a snapshot from dynamics performed with the Born Solvent model, with the N- and C-terminal residues represented by Corey-Pauling-Koltun structure. The distance between the {alpha} carbons of the terminal residues in each snapshot is marked. The D-Ala6-Ciona I GnRH structure was similar to Gly6-Ciona I (not shown).

 
It is, however, ~8-16% more than the average value found for the mammalian GnRH, modeled under identical conditions. In the gas-phase simulations this effect is most marked. This suggests that the primary sequence and, specifically, the Ser8 to Arg8 substitution has a large effect on retaining the rigidity of this type II' {beta}-turn.

Conformational Flexibility—Two methods were employed to assess conformational flexibility. The first examined the rotationally averaged collision cross-section of each peptide conformation during the course of the 1-ns dynamics run. The second, more conventional approach examined the root mean square deviation of the amino acids from their positions in an averaged structure. Both methods gave comparable results. The in vacuo data essentially confirms the findings discussed above. Over the course of the dynamics the peptides retain their compact conformations, and significantly, the size ordering remains L-Ala6 > D-Ala6 > Gly6. With the application of the solvent model, collision cross-sections increase for all the GnRH peptides, reflecting looser, and at times, elongated structures. The overall conformational flexibility of Ciona I GnRH was greater than that of the mammalian GnRH. Over the course of 1 ns of molecular dynamics at 300 K Ciona I GnRH exhibited more frequent conformational shifts than Gly6 Ciona I and mammalian GnRH (Fig. 6). In the dynamics runs, the average cross-section of Ciona I [M] (Fig. 6A) was 275.9 ± 12.2 Å2, and Gly6 Ciona I [M] (Fig. 6B) was 266.52 ± 5.2 Å2 (TABLE THREE). These trends are also seen in the [M+H]+protonated histidine forms. The D-Ala6 and Gly6 forms of Ciona I and mammalian GnRH retain a centrally configured loop in the solvent calculations (Fig. 5, B and C). Comparison with the data from mammalian GnRH (Fig. 5C) shows that this form of the peptide also appears somewhat stabilized during dynamics, although it also exhibits an increase in the N-C-terminal distance. The overall cross-section of mammalian GnRH is larger due to the Arg8. Interestingly, this bulky side chain of Arg8 is rather flexible, which supports data obtained from both the mouse (15) and the human (16) receptors that demonstrate Arg8 is integral to binding via an acidic residue in extracellular loop 3 (15, 16). The jump in cross-section in the earlier part of these dynamics measurements is expected, as the temperature of the low energy starting conformers is brought to thermal equilibration.



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 6.
Cross-section measurements obtained from Born Solvent model simulations for Ciona I [M] (A), Gly6-Ciona I [M] (B), and mammalian GnRH [M+H]+ (C). The dynamics runs were performed for 1 ns at 300 K. The data shown is obtained by determining the collision cross-section of the structures output from these calculations every 1 ps using the projection approximation (26). The initial spike observed here in each plot is an artifact attributable to the effect of rapidly heating the peptide up to 300 K from its 0 K low energy structure. These data correspond to the averaged values shown in TABLE THREE and nicely demonstrate the conformational flexibility of Ciona I compared with mammalian GnRH and to the Gly6-substituted form.

 
Although no attempt was made to model the interaction of the peptide with the receptor, it is apparent that the configurations of the isolated peptides can be related to the biological activity. The correlation between the experimentally measured cross-sections (TABLE TWO) and the stimulation of inositol phosphate data (TABLE ONE) is very good. The small tightly configured mammalian GnRH exhibits the strongest activity at the receptor, whereas the larger, "looser" Ciona I L-Ala analog is the weakest binder. The D-Ala6- and Gly6-Ciona I peptides are intermediate in cross-sections and binding affinity. This coupled with the fact that all the gas-phase structures have proximal N-C termini suggests that the gas-phase conformations are comparable with the receptor-bound form.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The importance of having the achiral glycine in position 6 of mammalian GnRH for biological activity was demonstrated in empirical studies three decades ago (1, 11, 27). Subsequent studies using N- and C-terminal-directed antibodies, fluorescence spectroscopy, molecular modeling, and NMR suggested that Gly6 was essential to allow GnRH to assume a type II' {beta}-turn conformation (1, 8, 11). Although GnRH receptors had not been cloned when this concept was proposed, these findings together with numerous structure-activity studies indicated that mammalian GnRH interacted with its cognate receptor in this type II' {beta}-turn conformation through the amino (pGlu-His-Trp-Ser) and carboxyl (Arg-Pro-Gly-NH2) terminal domains (1, 6–8). The subsequent elucidation of GnRH structural variants in vertebrates and protochordates reveals the conservation of these domains over more than 500 million years of evolution, thus supporting this conclusion (Fig. 1). Mutation of amino acids in cloned human and rat GnRH receptors has provided direct evidence for the interaction of individual amino acids in these two ligand domains with cognate receptor residues (pGlu with Asn212; His2 with Lys121 and Asp98; Trp3 with Trp280; Arg8 with Asp302; Gly.NH210 with Asn102) (8, 18, 19, 28-30). The receptor residues which bind the conserved pGlu, His, Trp, Ser, and Gly-NH2 of Ciona GnRHs are all conserved in the Ciona receptors as in fish, amphibian, and chicken receptors (8) with the exception of Asn212, which is a tyrosine in the Ciona A receptor.

In view of the stringent requirement of jawed vertebrate GnRH receptors for a glycine residue in position six to allow presentation of the N- and C-terminal domains in a folded conformation to the receptor, the presence of chiral amino acids in position six in jawless fish and protochordate GnRHs was unexpected. This finding suggests that the receptors of these species are able to interact with GnRH in an extended conformation. The similar low binding affinities (~1 µM) of mammalian, Ciona I, and Ciona III GnRHs at the Ciona A receptor supports this interpretation. The ability of the endogenous protochordate GnRHs and mammalian GnRH to stimulate spawning in protochordate species (2, 3, 9) also indicates that protochordate GnRH receptors do not distinguish mammalian and protochordate GnRHs. GnRHs with an achiral amino acid in position six were similarly active in mollusk species (31, 32). Interestingly, one of the protochordate GnRHs (Ciona VI) has Gly6 and is active in stimulating spawning in C. intestinalis (9). This finding supports our data demonstrating that the Ciona A GnRH receptor binds GnRHs with chiral (Ciona I and III) and achiral (mammalian GnRH) amino acids in position six equally well. This is consistent with our interpretations, as forms with chiral and achiral amino acids in position six can both assume a relaxed linear extended conformation. In contrast, we have shown here that the types of GnRH with chiral amino acids in position six have very low binding affinity at mammalian, avian, and teleostean GnRH receptors.

Our molecular modeling and IM-MS studies demonstrate a correlation between the propensity for type II' {beta}-turn conformation of GnRHs and their biological activity at the vertebrate receptors. Thus, Ciona I GnRH assumes a looser and, hence, less configured structure than mammalian GnRH and has poor binding affinity at vertebrate receptors. By comparing the collision cross-sections from experimental and calculated structures, it is apparent that L-Ala at position six induces steric hindrance to the formation of the more compact folded structure. This is supported by the larger Trp3-Leu7 distances found with Ciona I than for the Gly6 or D-Ala6 forms in vacuo and associated larger IM-MS collision cross-sections (TABLE TWO). We have previously investigated the gas-phase conformations of D-Trp-substituted mammalian GnRH by both experiment and calculation (33). Here we find that the D-Trp form adopts a much more compact geometry, with a type II' {beta}-turn, whereas the L-Trp variant is more extended due to steric effects caused by the bulky side chain in the naturally occurring form. The solvent calculations we present here on the Ciona I variants show these effects more dramatically. L-Ala at position six allows the backbone to open out in the course of the dynamics simulations, producing a much more elongated and less compact form of the peptide. In contrast, the D-Ala6- and Gly6-substituted Ciona I have more compact structure throughout the solvent dynamics. These findings concur with NMR studies on mammalian GnRH and D-Trp6-GnRH (34), but NMR is unable to distinguish structural differences between GnRHs without D-amino acids in position six. The extensive molecular modeling of Guarnieri and Weinstein (35) revealed that the conformational preference for a type II' {beta}-turn in the backbone of mammalian GnRH is significantly diminished by an Arg8 -> Lys8 substitution. Our gas-phase results also indicate the functional importance of Arg in the mammalian form, where its guanidinium side chain is flexible and forms favorable interactions across the polypeptide backbone, which assists the type II' {beta}-turn around glycine. Glycine residues are often found at turning points in protein structures, as the lack of side chain enables a tight turn to be made, but such turns are only successful if additional non-covalent interactions are present, as promoted here by Arg. This combination of Gly6 and Arg8 in mammalian GnRH produces a peptide configured with high affinity for the mammalian receptor. Substitution with D-Ala6 or Gly6 in Ciona I increases the affinity for the human receptor, since the peptide can now form a tighter turn. However, the presence of Ser in position eight rather than Arg precludes the very high affinity exhibited by the mammalian form at the mammalian receptor, due in part to the additional stabilization of the compact structure by Arg and the interaction of Arg with an acidic residue in extracellular loop 3 of the GnRH receptor, which contributes to configuration of the ligand at mammalian receptors (18, 19).

When the chiral amino acid (Ala) in position six of Ciona I GnRH was substituted with the achiral glycine or with D-Ala, which enhances the type II' {beta}-turn conformation, there was a marked increase in the binding affinity of the peptides at the vertebrate GnRH receptors. Moreover, the gas-phase studies indicated that these peptides assume a more compact configuration, whereas in solvent calculations they become more flexible. Thus, there is a correlation between biological activity and the tighter conformation of the peptides at the vertebrate receptors, whereas this situation does not pertain at the protochordate receptor.

These studies suggest that the early-evolved GnRH receptors of protochordates (and probably jawless fish) bind GnRH in a more extended configuration and that the subsequent evolution of the receptors in jawed vertebrates required a more compact configuration of GnRH for binding. The conservation of the N- and C-terminal domains of GnRHs in invertebrates and vertebrates (protochordates, jawless fish, jawed fish, amphibians, birds, and mammals) nevertheless indicates that these domains are functionally important for binding and activating the GnRH receptor. As mentioned earlier, most of the binding sites for the N- and C-terminal GnRH residues in the human and vertebrate receptors are present in the tunicate GnRH receptor. However, the non-requirement for an achiral amino acid in position six in protochordates and jawless fish, but the requirement for an achiral Gly in higher vertebrates indicates that, although the N and C domains of GnRH interact through the same or similar sites in the receptor, these are more closely positioned in the higher vertebrates (which require the folded conformation) than in protochordates and jawless fish (which bind less configured forms of the peptide equally well and with lower affinity). It is possible, therefore, that the protochordate GnRH receptor is also less compact due to fewer transmembrane domain interactions. A major transmembrane domain interaction in GPCRs is between Asp2.50 in TM2 and Asn7.50 in TM7. These are reciprocally mutated to Asn and Asp in the human GnRH receptor, and these residues are critical for receptor function (36). In the Ciona GnRH receptors Asn is present in TM2, but His replaces Asp in TM7. In addition to this TM interaction, we recently identified Met227 (TM5), Phe272 (TM6), Phe276 (TM6), and Ile322 (TM7) as interacting residues in the human GnRH receptor that alter ligand affinity and selectivity when mutated (37). Phe276 is conserved between the tunicate and human GnRH receptors. Met132 is Val, Met227 is Thr, Phe272 is Ile, and Ile322 is Val in the Ciona A receptor. These residue differences may, therefore, contribute to reduced ligand affinity and selectivity in the Ciona A receptor and will be the subject of future studies.

In addition to its direct activation of the gonads in Ciona, GnRH appears to serve a role as a pheromone in another protochordate, Saccoglossus (38), and in a mollusk (Chiton) (31). Tunicate spawning is precisely correlated with light cycles, and light appears to stimulate GnRH secretion (39), which is secreted directly from nerve endings onto gonadal cells. In vertebrates, however, GnRH has been co-opted to serve a more complex neuroendocrine role where external environmental factors (e.g. light) stimulate secretion of GnRH into portal vessels to stimulate secretion of pituitary gonadotropins and ultimately the gonads. The dilution of GnRH in the portal vessels may, thus, have driven the evolution of the more compact GnRH with higher affinity binding. However, some of the earlier-evolved functions seen in protochordates appear to have been retained in vertebrates as GnRH and GnRH receptors are present in the gonads of fish, amphibians, and mammals (5-7), suggesting direct effects on gonads (40).

It is, therefore, evident that the GnRH structure existed very early in evolution and was co-opted in diverse ways to regulate reproduction. During at least 600 million years of evolution the N and C termini of GnRH have been conserved as functional domains for binding and activating cognate receptors to accomplish these functions. However, about 400 million years ago a single substitution of the chiral amino acid in position six of GnRH in jawless fish by the achiral glycine facilitated a type II' {beta}-turn conformation of GnRH to allow spatially close interaction of these functional domains of GnRH with its receptor, in contrast to the interaction of more extended GnRH structures with receptors in earlier-evolved species. This notion was supported by studies on receptor binding affinities and IM-MS/molecular modeling conformations of GnRHs with Ala, Gly, and D-Ala in position six that showed a close correlation between binding affinity at vertebrate GnRH receptors and their propensity to form a type II' {beta}-turn conformation. Thus, an apparently insignificant substitution of a single amino acid at a site remote from the binding and activation domains of GnRH can have a major effect on the conformation of the ligand and affect its interaction with the receptor binding sites. These findings emphasize the importance of subtle changes in three-dimensional structural evolution of a peptide ligand, which is likely to also pertain to other peptide ligands and their receptors.


   FOOTNOTES
 
* This work was supported by the Engineering and Physical Sciences Research Council (to P. E. B.), the Medical Research Councils of the United Kingdom and South Africa (to R. P. M.), and the National Science Foundation (to M. T. B.) for support. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed. Tel.: 441312426240; Fax: 441312426231; E-mail: r.millar{at}hrsu.mrc.ac.uk.

2 The abbreviations used are: GnRH, gonadotropin-releasing hormone; pGlu, pyroglutamic acid; IM-MS, ion mobility-mass spectrometry. Back

3 During revision of this manuscript Tello et al. (41) reported the cloning of these two receptors and two additional receptors which are selective for the various tunicate GnRHs. Back


   ACKNOWLEDGMENTS
 
We are grateful to Yuka Kitajima for technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sealfon, S. C., Weinstein, H., and Millar, R. P. (1997) Endocr. Rev. 18, 180-205[Abstract/Free Full Text]
  2. Powell, J. F., Reska-Skinner, S. M., Prakash, M. O., Fischer, W. H., Park, M., Rivier, J. E., Craig, A. G., Mackie, G. O., and Sherwood, N. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10461-10464[Abstract/Free Full Text]
  3. Craig, A. G., Fischer, W. H., Park, M., Rivier, J. E., Musselman, B. D., Powell, J. F., Reska-Skinner, S. M., Prakash, M. O., Mackie, G. O., and Sherwood, N. M. (1997) FEBS Lett. 413, 215-225[CrossRef][Medline] [Order article via Infotrieve]
  4. Terakado, K. (2001) Gen. Comp. Endocrinol. 124, 277-284[CrossRef][Medline] [Order article via Infotrieve]
  5. Hsueh, A. J., and Schaeffer, J. M. (1985) J. Steroid Biochem. 23, 757-764[Medline] [Order article via Infotrieve]
  6. King, J. A., and Millar, R. P. (1997) in GnRH Neurones: Gene to Behavior (Parhar, I. S., and Sakuma, Y., eds) pp. 51-77, Brain Shuppan, Toyko
  7. Millar, R. P., Troskie, B., Sun, Y.-M., Ott, T., Wakefield, I., Myburgh, D., Pawson, A., Davidson, J. S., Katz, A., Hapgood, J., Illing, N., Weinstein, H., Sealfon, S. C., Peter, R. E., Terasawa, E., and King, J. A. (1997) in Advances in Comparative Endocrinology. Proceedings of the XIII International Congress of Comparative Endocrinology (Kawashima, S., and Kikuyama, S., eds), pp. 15-27, Monduzzi Editore, Yokohama, Japan
  8. Millar, R. P., Lu, Z.-L., Pawson, A. J., Flanagan, C. A., Morgan, K., and Maudsley, S. (2004) Endocr. Rev. 25, 235-275[Abstract/Free Full Text]
  9. Adams, B. A., Tello, J. A., Erchegyi, J., Warby, C., Hong, D. J., Akinsanya, K. O., Mackie, G. O., Vale, W., Rivier, J. E., and Sherwood, N. M. (2003) Endocrinology 144, 1907-1919[Abstract/Free Full Text]
  10. Iwakoshi, E., Takuwa-Kuroda, K., Fujisawa, Y., Hisada, M., Ukena, K., Tsutsui, K., and Minakata, H. (2002) Biochem. Biophys. Res. Commun. 291, 1187-1193[CrossRef][Medline] [Order article via Infotrieve]
  11. Karten, M. J., and Rivier, J. E. (1986) Endocr. Rev. 7, 44-66[Abstract/Free Full Text]
  12. Pfleger, K. D., Bogerd, J., and Millar, R. P. (2002) Mol. Endocrinol. 16, 2155-2162[Abstract/Free Full Text]
  13. Pawson, A. J., Maudsley, S. R., Lopes, J., Katz, A. A., Sun, Y. M., Davidson, J. S., and Millar, R. P. (2003) Endocrinology 144, 3860-3871[Abstract/Free Full Text]
  14. Chi, L., Zhou, W., Prikhozhan, A., Flanagan, C., Davidson, J. S., Golembo, M., Illing, N., Millar, R. P., and Sealfon, S. C. (1993) Mol. Cell. Endocrinol. 91, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  15. Sun, Y. M., Flanagan, C. A., Illing, N., Ott, T. R., Sellar, R., Fromme, B. J., Hapgood, J., Sharp, P., Sealfon, S. C., and Millar, R. P. (2001) J. Biol. Chem. 276, 7754-7761[Abstract/Free Full Text]
  16. Bogerd, J., Diepenbroek, W. B., Hund, E., van Oosterhout, F., Teves, A. C., Leurs, R., and Blomenrohr, M. (2002) Endocrinology 143, 4673-4682[Abstract/Free Full Text]
  17. Kusakabe, T., Mishima, S., Shimada, I., Kitajima, Y., and Tsuda, M. (2003) Gene (Amst.) 322, 77-84[CrossRef][Medline] [Order article via Infotrieve]
  18. Flanagan, C. A., Becker, II, Davidson, J. S., Wakefield, I. K., Zhou, W., Sealfon, S. C., and Millar, R. P. (1994) J. Biol. Chem. 269, 22636-22641[Abstract/Free Full Text]
  19. Fromme, B. J., Katz, A. A., Roeske, R. W., Millar, R. P., and Flanagan, C. A. (2001) Mol. Pharmacol. 60, 1280-1287[Abstract/Free Full Text]
  20. Wyttenbach, T., Kemper, P. R., and Bowers, M. T. (2001) Int. J. Mass Spectrom. Ion Process. 212, 13-23
  21. Mason, E. A., and MacDaniel, E. W. (1988) Transport Properties of Ions in Gases, John Wiley & Sons, Inc., New York
  22. Ponder, J. W., and Case, D. A. (2003) Adv. Protein Chem. 66, 27-85[Medline] [Order article via Infotrieve]
  23. Wang, J., Cieplak, P., and Kollman, P. A. (2000) J. Comput. Chem. 21, 1049-1074[CrossRef]
  24. Harrison, A. G. (1997) Mass Spectrom. Rev. 16, 201-217[CrossRef]
  25. Bashford, D., and Case, D. A. (2000) Annu. Rev. Phys. Chem. 51, 129-152[CrossRef][Medline] [Order article via Infotrieve]
  26. Wyttenbach, T., and Bowers, M. T. (2003) Top. Curr. Chem. 255, 207-232
  27. Monahan, M. W., Amoss, M. S., Anderson, H. A., and Vale, W. (1973) Biochemistry 12, 4616-4620[CrossRef][Medline] [Order article via Infotrieve]
  28. Hoffmann, S. H., ter Laak, T. T., Kuhne, R., Reilander, H., and Beckers, T. (2000) Mol. Endocrinol. 14, 1099-1115[Abstract/Free Full Text]
  29. Zhou, W., Rodic, V., Kitanovic, S., Flanagan, C. A., Chi, L., Weinstein, H., Maayani, S., Millar, R. P., and Sealfon, S. C. (1995) J. Biol. Chem. 270, 18853-18857[Abstract/Free Full Text]
  30. Davidson, J. S., McArdle, C. A., Davies, P., Elario, R., Flanagan, C. A., and Millar, R. P. (1996) J. Biol. Chem. 271, 15510-15514[Abstract/Free Full Text]
  31. Gorbman, A., Whiteley, A., and Kavanaugh, S. (2003) Gen. Comp. Endocrinol. 131, 62-65[CrossRef][Medline] [Order article via Infotrieve]
  32. Pazos, A. J., and Mathieu, M. (1999) Gen. Comp. Endocrinol. 113, 112-120[CrossRef][Medline] [Order article via Infotrieve]
  33. Polfer, N. C., Haselmann, K. F., Langridge-Smith, P. R. R., and Barran, P. E. (2005) Mol. Physiol. 103, 1481-1489[CrossRef]
  34. Maliekal, J. C., Jackson, G. E., Flanagan, C. A., and Millar, R. P. (1997) S. Afr. J. Chem. 50, 217-219
  35. Guarnieri, F., and Weinstein, H. (1996) J. Am. Chem. Soc. 118, 5580-5589[CrossRef]
  36. Zhou, W., Flanagan, C., Ballesteros, J. A., Konvicka, K., Davidson, J. S., Weinstein, H., Millar, R. P., and Sealfon, S. C. (1994) Mol. Pharmacol. 45, 165-170[Abstract]
  37. Lu, Z. L., Gallagher, R., Sellar, R., Coetsee, M., and Millar, R. R. (2005) J. Biol. Chem. 280, 29796-29803[Abstract/Free Full Text]
  38. Cameron, C. B., Mackie, G. O., Powell, J. F., Lescheid, D. W., and Sherwood, N. M. (1999) Gen. Comp. Endocrinol. 114, 2-10[CrossRef][Medline] [Order article via Infotrieve]
  39. Oh da, Y., Wang, L., Ahn, R. S., Park, J. Y., Seong, J. Y., and Kwon, H. B. (2003) Mol. Cell. Endocrinol. 205, 89-98[CrossRef][Medline] [Order article via Infotrieve]
  40. Dalkin, A. C., Bourne, G. A., Pieper, D. R., Regiani, S., and Marshall, J. C. (1981) Endocrinology 108, 1658-1664[Abstract/Free Full Text]
  41. Tello, J. A., Rivier, J. E., and Sherwood, N. M.. (2005) Endocrinology 146, 4061-4073[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
P.-S. Tsai and L. Zhang
The Emergence and Loss of Gonadotropin-Releasing Hormone in Protostomes: Orthology, Phylogeny, Structure, and Function
Biol Reprod, November 1, 2008; 79(5): 798 - 805.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. Lopez de Maturana, A. J. Pawson, Z.-L. Lu, L. Davidson, S. Maudsley, K. Morgan, S. P. Langdon, and R. P. Millar
Gonadotropin-Releasing Hormone Analog Structural Determinants of Selectivity for Inhibition of Cell Growth: Support for the Concept of Ligand-Induced Selective Signaling
Mol. Endocrinol., July 1, 2008; 22(7): 1711 - 1722.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/46/38569    most recent
M503086200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barran, P. E.
Right arrow Articles by Millar, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barran, P. E.
Right arrow Articles by Millar, R. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement